G Du1, L Zhou, S Li, Y Mao, H Chen. 1. Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China. dghong@online.sh.cn
Abstract
OBJECTIVE: To elucidate the clinical features and treatment of Hemangiopericytomas (HPCs) in the central nervous system. METHODS: Twenty-six HPC operations performed at Huashan Hospital from January 1993 to June 1999 were analyzed retrospectively, and a review of relevant literatures was done. RESULTS: Among the 26 cases, total tumor removal was achieved in 24 cases, and subtotal removal in 2 cases. Postoperatively, neurological symptoms were improved or unchanged in 21 cases, worsened in 4 cases, and pneumonia caused death in 1 case. Eighteen patients received postoperative radiotherapy. Eighteen patients were followed up from 1 month to 58 months (average, 22 months). During the follow-up period, 2 patients presented one or more distant metastasis, and one patient died of recurrence. CONCLUSION: Surgical management is the best choice for treatment of patients with HPCs. Postoperative radiotherapy can postpone the risk of tumor recurrence.
OBJECTIVE: To elucidate the clinical features and treatment of Hemangiopericytomas (HPCs) in the central nervous system. METHODS: Twenty-six HPC operations performed at Huashan Hospital from January 1993 to June 1999 were analyzed retrospectively, and a review of relevant literatures was done. RESULTS: Among the 26 cases, total tumor removal was achieved in 24 cases, and subtotal removal in 2 cases. Postoperatively, neurological symptoms were improved or unchanged in 21 cases, worsened in 4 cases, and pneumonia caused death in 1 case. Eighteen patients received postoperative radiotherapy. Eighteen patients were followed up from 1 month to 58 months (average, 22 months). During the follow-up period, 2 patients presented one or more distant metastasis, and one patient died of recurrence. CONCLUSION: Surgical management is the best choice for treatment of patients with HPCs. Postoperative radiotherapy can postpone the risk of tumor recurrence.
Authors: K N Fountas; E Kapsalaki; M Kassam; C H Feltes; V G Dimopoulos; J S Robinson; J R Smith Journal: Neurosurg Rev Date: 2006-01-04 Impact factor: 3.042